Q1 2023 Non-GAAP Operating Income

Revenues by Activity and Geographical Area | 34 | $ millions Q1-22 Q2-22 Q3-22 Q4-22 Q1-23 North America Segment 1,737 1,904 1,809 2,002 1,766 Generic products 899 1,026 806 818 824 AJOVYⓇ 36 49 57 75 49 AUSTEDOⓇ 154 204 260 344 170 BENDEKAⓇ/TREANDAⓇ 82 83 77 75 63 COPAXONEⓇ 86 94 105 101 76 Anda 342 308 371 450 424 Other 139 139 133 138 160 Europe Segment 1,156 1,171 1,069 1,129 1,184 Generic products 876 873 803 914 932 AJOVYⓇ 30 29 30 35 36 COPAXONE® 72 72 63 61 59 Respiratory 71 65 62 75 68 Other 107 131 111 43 89 International Markets Segment 492 454 475 482 492 Generic products 388 394 393 411 400 AJOVYⓇ 6 10 6 13 10 COPAXONE® 10 9 9 7 12 Other Other Total Teva 88 40 67 51 70 275 257 241 272 219 3,661 3,786 3,595 3,884 3,661 teva

View entire presentation